Hong Sukwoo, Laack Nadia, Mahajan Anita, Choby Garret, O'Brien Erin, Stokken Janalee, Janus Jeffrey, Van Gompel Jamie J
Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota, USA.
Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
World Neurosurg. 2023 Mar;171:e644-e653. doi: 10.1016/j.wneu.2022.12.081. Epub 2022 Dec 20.
To assess the early outcomes of the following 2 types of proton therapy: passive scattering proton therapy (PSPT) and pencil beam proton therapy (PBPT).
The consecutive patients who had surgery in our facility were retrospectively reviewed.
Thirty-two patients were identified (PBPT 22 patients [69%]). The mean (±standard deviation [SD]) tumor size was 3.8 ± 1.8 cm, and the most common location was the upper clivus (41%). Four cases (13%) were revision surgeries referred from elsewhere, and 2 cases underwent additional surgery elsewhere to achieve near-total resection before radiation. The cerebrospinal fluid leak occurred in 3 patients (9%). The mean (±SD) prescribed dose of PSPT and PBPT was 74 ± 3 Gy and 72 ± 3 Gy, respectively (P = 0.07). The mean (±SD) fractionation of PSPT and PBPT was 39 ± 2 and 36 ± 2, respectively (P = 0.001). Radiation toxicities were recorded in endocrine (11 patients [34%]), ophthalmic (3 patients [9%]), otologic (7 patients [22%]), and radiation necrosis (4 patients [13%]). PSPT was associated with endocrinopathy (odds ratio [OR], 10.5; 95% confidence interval, 1.86-59.4, P = 0.008), and radiation dose was associated with otologic toxicity (OR 1.57; 95% confidence interval, 1.02-2.44; P = 0.04). The gross-near total resection group had better progression-free survival than the subtotal resection group regardless of radiation therapy (P = 0.01). Overall, 3-year progression-free survival was 73%, and 5-year overall survival was 93%.
The PBPT group showed comparable outcome to the PSPT group. The degree of resection was more important than the modality of proton therapy. Further follow-up and cases are necessary to evaluate the benefit of PBPT.
评估以下两种质子治疗方式的早期疗效:被动散射质子治疗(PSPT)和笔形束质子治疗(PBPT)。
对在我们机构接受手术的连续患者进行回顾性分析。
共纳入32例患者(PBPT组22例[69%])。肿瘤平均(±标准差[SD])大小为3.8±1.8 cm,最常见部位为斜坡上部(41%)。4例(13%)为从其他地方转诊来的翻修手术患者,2例在放疗前在其他地方接受了额外手术以实现近全切除。3例患者(9%)发生脑脊液漏。PSPT和PBPT的平均(±SD)处方剂量分别为74±3 Gy和72±3 Gy(P = 0.07)。PSPT和PBPT的平均(±SD)分割次数分别为39±2和36±2(P = 0.001)。记录到的放射毒性包括内分泌(11例患者[34%])、眼科(3例患者[9%])、耳科(7例患者[22%])和放射性坏死(4例患者[13%])。PSPT与内分泌病变相关(优势比[OR],10.5;95%置信区间,1.86 - 59.4,P = 0.008),放射剂量与耳科毒性相关(OR 1.57;95%置信区间,1.02 - 2.44;P = 0.04)。无论放疗情况如何,大体近全切除组的无进展生存期均优于次全切除组(P = 0.01)。总体而言,3年无进展生存率为73%,5年总生存率为93%。
PBPT组的疗效与PSPT组相当。切除程度比质子治疗方式更重要。需要进一步随访和增加病例数来评估PBPT的益处。